Enhanced COPD Management in Suspected Lung Cancer Patients

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorDitte Krag-Hansen

About this trial

Identifying and treating COPD in patients undergoing lung cancer evaluation is crucial. Early intervention could lead to better management of both diseases, improving health status, reducing healthcare costs, and potentially increasing survival rates.

This study aims to assess the impact of early diagnosis and optimal treatment of COPD on clinical outcomes in patients under evaluation for lung cancer. The study will combine information through an open-label RCT at the Lung Cancer Investigation Unit at Lillebaelt Hospital Vejle.

The findings could inform clinical practice by emphasizing the importance of integrated care approaches for patients with coexisting COPD and lung cancer, ultimately leading to better health outcomes.

Eligibility criteria

Qualifiers

Undergoing diagnostic evaluation for suspected lung cancer

Spirometry showing obstructive airflow limitation (FEV₁/FVC < 75 % or FEV₁ < 80 %, and no reversibility) at the first outpatient visit at the lung cancer evaluation

Disqualifiers

Presence of significant comorbidities that may interfere with diagnostic procedures or spirometry

Pregnant or breastfeeding women

Trial design

Treatments tested in this trial

  • Tailored COPD consultations

Treatment groups

280 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Ditte Krag-Hansen

Lead sponsor

Region of Southern Denmark

Sponsor institution

AstraZeneca

Collaborator

Sygehus Lillebaelt

Collaborator